Recombinant protective antigen 102 (rPA102): profile of a second-generation anthrax vaccine

Author: Keitel, Wendy A

Source: Expert Review of Vaccines, Volume 5, Number 4, August 2006 , pp. 417-430(14)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Recent terrorist attacks involving the use of Bacillus anthracis spores have stimulated interest in the development of new vaccines for anthrax prevention. Studies of the pathogenesis of anthrax and of the immune responses following infection and immunization underscore the pivotal role that antibodies to the protective antigen play in protection. The most promising vaccine candidates contain purified recombinant protective antigen. Clinical trials of one of these, recombinant protective antigen (rPA)102, are underway. Initial results suggest that rPA102 is well tollerated and immunogenic. Additional trials are necessary to identify optimal formulations and immunization regimens for pre- and postexposure prophylaxis. Future licensure of these and other candidate vaccines will depend on their safety and immunogenicity profiles in humans, and their ability to confer protection in animal models of inhalational anthrax.

Keywords: anthrax; anthrax vaccine; Bacillus anthracis; immunization; recombinant protective antigen

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14760584.5.4.417

Publication date: 2006-08-01

More about this publication?

Expert Review of Vaccines provides expert reviews on the clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines in bioterrorism.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites